Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of Cadonilimab(AK104) in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Trial Details

NCT ID
NCT06406634
Phase
PHASE2
Sponsor
Hunan Cancer Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Cadonilimab
  • Lenvatinib
Locations (sample)
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • The written informed consent form should be signed before a subject participates in the trial;
  • Histologically/cytologically confirmed HCC or cirrhosis meeting the clinical diagnostic criteria of HCC by the American Association for the Study o…
  • According to the Chinese Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2022 edition), eligible for China liver cancer staging (CN…
  • Child-Pugh A or B;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →